The global biopharmaceuticals contract manufacturing market size is expected to reach USD 27.3 billion by 2030, growing at a CAGR of 5.2% from 2022 to 2030. Growing biopharmaceutical pipeline and lack of adequate manufacturing capabilities are two key factors that are driving partnership between large molecule manufacturers and Contract Manufacturing Organizations (CMOs). Contract manufacturers are engaged in broadening their service portfolio to meet the companies' demands with respect to regulatory standards and new services. The pandemic has, however, also had some negative knock-on effects as budgets and resources are diverted to “COVID products” at the expense of other biologics projects in development for other therapeutic areas.
The reliance of companies on CMOs for the production of biologics and biosimilars is expected to rise during the forecast period as a consequence of changes adopted by the CMOs. This is evident through growing investment in collaborations of companies with CMOs as well as continuous efforts taken up for expanding the service portfolio. The supply chain of biopharmaceuticals remained robust and was largely unaffected worldwide during the coronavirus outburst. Also, biopharmaceutical contract manufacturers are observing increased demand related to COVID-19 vaccine and therapeutics. Thus, the future holds numerous opportunities for the market. For instance, in 2020, AstraZeneca and Oxford Biomedica signed a one-year clinical and commercial supply agreement for the manufacturing of AstraZeneca’s COVID-19 vaccine candidate, AZD1222.
The future growth of the market is highly dependent on the promising opportunities offered by the biopharmaceutical industry, bioprocessing industry, and contract service industry. Expansion of fill-and-finish services and increasing robustness of venture capital investments for the life science sector are two important opportunities that are anticipated to drive the market. For instance, in 2019, Shanghai HaiHe Biopharma Co. Ltd. raised USD 146.6 million as venture capital for its large cancer drug portfolio, which it shall utilize along with its outsourcing partner Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
The reliance of companies on CMOs for the production of biologics and biosimilars is expected to rise during the forecast period as a consequence of changes adopted by the CMOs. This is evident through growing investment in collaborations of companies with CMOs as well as continuous efforts taken up for expanding the service portfolio. The supply chain of biopharmaceuticals remained robust and was largely unaffected worldwide during the coronavirus outburst. Also, biopharmaceutical contract manufacturers are observing increased demand related to COVID-19 vaccine and therapeutics. Thus, the future holds numerous opportunities for the market. For instance, in 2020, AstraZeneca and Oxford Biomedica signed a one-year clinical and commercial supply agreement for the manufacturing of AstraZeneca’s COVID-19 vaccine candidate, AZD1222.
The future growth of the market is highly dependent on the promising opportunities offered by the biopharmaceutical industry, bioprocessing industry, and contract service industry. Expansion of fill-and-finish services and increasing robustness of venture capital investments for the life science sector are two important opportunities that are anticipated to drive the market. For instance, in 2019, Shanghai HaiHe Biopharma Co. Ltd. raised USD 146.6 million as venture capital for its large cancer drug portfolio, which it shall utilize along with its outsourcing partner Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Biopharmaceuticals Contract Manufacturing Market Report Highlights
- Mammalian-based biopharmaceutical contract manufacturing captured the largest market share about 58% in 2021 owing to the high penetration of mammalian expression systems for biologics development.
- Out of all the services offered in this market, process development contributed to the largest share of 33% in 2021, owing to high capital investment, especially in downstream process.
- Biologics contract manufacturing dominated its counterpart segment owing to higher demand for biologics production. However, the biosimilar segment is growing with a lucrative CAGR of 8.3% due to cost-saving advantages associated with biosimilars development.
- The presence of an effective regulatory framework for biologics development in the U.S. has resulted in a large share of the North America market of 34.0% in 2021.
- However, Asia Pacific is expected to emerge as the fastest-growing regional market with a CAGR of 5.8% from 2022 to 2030, owing to developing economies such as India and China incorporating developments to sustain the competition.
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Research Methodology
Chapter 3 Market Variables, Trends& Scope
Chapter 4 Biopharmaceuticals Contract Manufacturing Market: Source Estimates & Trend Analysis
Chapter 5 Biopharmaceuticals Contract Manufacturing Market: Service Estimates & Trend Analysis
Chapter 6 Biopharmaceuticals Contract Manufacturing Market: Product Estimates & Trend Analysis
Chapter 7 Biopharmaceuticals Contract Manufacturing Market: Regional Estimates & Trend Analysis, by Service, Source, & Product
Chapter 8 Competitive Landscape
Companies Mentioned
- Boehringer Ingelheim GmbH
- Lonza
- Inno Biologics Sdn Bhd
- Rentschler Biotechnologie GmbH
- Jrs Pharma
- Celonic AG
- Agc Biologics
- Biomeva GmbH
- Cmc Biologics
- Financial Performance of Agc
- Probiogen
- Fujifilm Diosynth Biotechnologies U.S.A. Inc.
- Toyobo Co. Ltd.
- Samsung Biologics
- Thermo Fisher Scientific, Inc.
- Binex Co. Ltd.
- Wuxi Biologics
- Abbvie, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 193 |
| Published | April 2022 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 18.18 Billion |
| Forecasted Market Value ( USD | $ 27.3 Billion |
| Compound Annual Growth Rate | 5.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 18 |
